Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | AGXT | P21549 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7789774 | 0.84 | MAOB (0.41) | MAOBPARP10IDO1AGXTNR4A2 | |
| SCHEMBL7792917 | 0.84 | NPC1 (0.51) | — | |
| SCHEMBL7793844 | 0.80 | IDO1 (0.44) | MAOBIDO1AGXT | |
| SCHEMBL7792899 | 0.76 | ALDH1A1 (0.62) | MAOBPARP10IDO1SCN9A | |
| SCHEMBL7792922 | 0.76 | MAOB (0.45) | MAOBPARP10IDO1AGXTMAOA | |
| SCHEMBL11911577 | 0.76 | CNR2 (0.51) | — | |
| SCHEMBL7347119 | 0.76 | RAB9A (0.54) | MAOBPARP10AGXT | |
| SCHEMBL9278982 | 0.70 | IDO1 (0.60) | MAOBPARP10IDO1AGXTTAAR1 | |
| SCHEMBL38657612 | 0.70 | NPC1 (0.51) | — | |
| SCHEMBL29747227 | 0.70 | HCAR2 (0.60) | MAOBPARP10IDO1AGXTTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010044547-A1 | Antiviral protease inhibitors | MEDIVIR AB | 2001-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010044547-A1 | Antiviral protease inhibitors | PEPD, PREP, CTSL | MAOB 1597/4885PARP10 1036/4885IDO1 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.